Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A Phase 3b Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Omadacycline IV/PO to Moxifloxacin IV/PO for Treating Adult Subjects with Community-Acquired Bacterial Pneumonia (CABP)

    Summary
    EudraCT number
    2020-002986-32
    Trial protocol
    BG   HR   HU   PL  
    Global end of trial date
    27 Mar 2024

    Results information
    Results version number
    v1(current)
    This version publication date
    16 Feb 2025
    First version publication date
    16 Feb 2025
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    PTK0796-CABP-19302
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT04779242
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    Paratek Pharma, LLC
    Sponsor organisation address
    75 Arlington Street, Suite 500, Boston, United States, 02116
    Public contact
    Chief Development and Regulatory, Paratek Pharma, LLC, +1 6172750040, randy.brenner@paratekpharma.com
    Scientific contact
    Chief Development and Regulatory, Paratek Pharma, LLC, +1 6172750040, randy.brenner@paratekpharma.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    17 Sep 2024
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    27 Mar 2024
    Global end of trial reached?
    Yes
    Global end of trial date
    27 Mar 2024
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    The primary objective of this study was to demonstrate that iv to po omadacycline was non-inferior to iv to po moxifloxacin in the treatment of adults with PORT Risk Class III and IV CABP. The secondary objectives were: • To evaluate the safety of omadacycline in the treatment of adult subjects with CABP in the Safety population. • To evaluate the clinical response according to the identified causative pathogen. • To evaluate the pharmacokinetics (PK) of omadacycline in adult subjects with CABP.
    Protection of trial subjects
    This clinical study was designed and implemented and reported in accordance with the International Council for Harmonisation (ICH) Harmonised Tripartite Guidelines for Good Clinical Practice (GCP), with applicable local regulations (including European Directive 2001/20/EC, United States [US] Code of Federal Regulations [CFR] Title 21, and Japanese Ministry of Health, Labor, and Welfare), and with the ethical principles laid down in the Declaration of Helsinki. The investigator provided protection of the subjects by following all applicable regulations. These regulations were available upon request from the sponsor. The ICF was reviewed by the sponsor and approved by the IRB/IEC/REB. Before any procedures specified in the protocol were performed, a subject must have: • Been informed of all pertinent aspects of the study and all elements of informed consent. • Been given time to ask questions and time to consider the decision to participate. • Voluntarily agreed to participate in the study. • Signed and dated an IRB/IEC/REB approved ICF.
    Background therapy
    A total of 5.0% omadacycline subjects and 2.7% moxifloxacin subjects received concomitant antibacterial medications between the first infusion of test article and the EOT visit (CE-EOT population) and 5.1% omadacycline subjects and 3.0% moxifloxacin subjects received concomitant antibacterial medications between the first infusion of test article and the PTE visit (CE-PTE population).
    Evidence for comparator
    Moxifloxacin (400 mg iv every 24 hours [q24h] with the option to transition to 400 mg po q24h) was chosen as the comparator given the wide acceptance of fluoroquinolone monotherapy as a safe, first-line option for treating subjects with CABP. Moxifloxacin provides a broad spectrum of activity against respiratory pathogens that are causative agents of CABP, including typical (eg, Streptococcus pneumoniae) and atypical (eg, Legionella, Chlamydophila, and Mycoplasma spp.) pathogens, with a similar spectrum of activity to that of omadacycline. Like omadacycline, moxifloxacin has both iv and po formulation options and was administered once daily. Moxifloxacin was also the comparator in the registrational CABP trial supporting approval of Nuzyra.
    Actual start date of recruitment
    25 Feb 2021
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Poland: 16
    Country: Number of subjects enrolled
    Croatia: 27
    Country: Number of subjects enrolled
    Bulgaria: 190
    Country: Number of subjects enrolled
    Hungary: 3
    Country: Number of subjects enrolled
    Georgia: 246
    Country: Number of subjects enrolled
    Russian Federation: 4
    Country: Number of subjects enrolled
    Serbia: 91
    Country: Number of subjects enrolled
    Ukraine: 93
    Worldwide total number of subjects
    670
    EEA total number of subjects
    236
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    334
    From 65 to 84 years
    309
    85 years and over
    27

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    Subjects were enrolled at a total of 40 sites in Bulgaria (9 sites), Croatia (3 sites), Georgia (6 sites), Hungary (3 sites), Poland (2 sites), Russian Federation (2 sites), Serbia (7 sites), and Ukraine (8 sites). The first subject, first visit was on 25Feb2021.

    Pre-assignment
    Screening details
    Key inclusion criteria: age >=18 yr; at least 3 symptoms (cough, purulent sputum, dyspnea, chest pain); at least 2 abnormal vital signs (fever or hypothermia, hypotension, HR >90 bpm, RR >20 breaths/min); at least 1 finding associated with CABP; elevated WBC, leukopenia, or elevated immature neutrophils; PORT Risk Class III or IV.

    Period 1
    Period 1 title
    Overall trial (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Randomised - controlled
    Blinding used
    Double blind
    Roles blinded
    Investigator, Subject
    Blinding implementation details
    The iv treatment phase: double-blind, double-dummy design with placebo infusions matched to active omadacycline and moxifloxacin infusions. All iv infusions were administered by qualified blinded personnel. The po treatment phase: double-blind, double-dummy design using omadacycline placebo comparator tablets of matching size and shape to active omadacycline tablets and matching over-encapsulated placebo and active moxifloxacin tablets.

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Omadacycline
    Arm description
    The ITT population included all 336 subjects randomized to the omadacycline group. The ITT population was used for analysis of demographic and baseline characteristics and efficacy. The safety population included all randomized subjects who received at least 1 dose of test article (336 subjects).
    Arm type
    Experimental

    Investigational medicinal product name
    Omadacycline
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Powder for infusion, Tablet
    Routes of administration
    Oral use, Intravenous use
    Dosage and administration details
    The iv-treatment phase (minimum of 2 days) followed a double-blind, double-dummy design for omadacycline. Infusions of omadacycline or matched placebo were administered continuously, without interruptions, over 30 minutes (± 5 minutes). If once a day (QD) dosing was selected, the 200 mg infusion of omadacycline or matched placebo was administered continuously, without interruptions, over 60 minutes (± 5 minutes). If BID dosing was selected, 100 mg infusion was administered BID on Day 1 followed by 100 mg iv on Day 2. The po treatment phase employed a double-blind, double-dummy design using omadacycline placebo comparator tablets of matching size and shape to active omadacycline tablets. The first po dose was given in the morning 12 to 24 hours after the last iv dose. To maintain investigator and subject blinding, subjects on both arms received 2 tablets and 1 over-encapsulated tablet in the morning.

    Arm title
    Moxifloxacin
    Arm description
    The ITT population included all 334 subjects randomized to the moxifloxacin group. The ITT population was used for analysis of demographic and baseline characteristics and efficacy. The safety population included all randomized subjects who received at least 1 administration of test article (332 subjects). Two subjects were excluded from the safety population because they did not receive test article.
    Arm type
    Active comparator

    Investigational medicinal product name
    Moxifloxacin
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for infusion, Tablet
    Routes of administration
    Infusion , Oral use
    Dosage and administration details
    The iv-treatment phase (minimum of 2 days) followed a double-blind, double-dummy design for moxifloxacin 400 mg QD and matched placebo were administered continuously without interruptions over 60 minutes (± 5 minutes). During the first 24 hours of iv treatment, if twice a day dosing (BID) was selected, subjects on the moxifloxacin treatment arm received an additional placebo infusion to match the t=12 hours infusion. Infusions of moxifloxacin or matched placebo were administered continuously, without interruptions, over 60 minutes (± 5 minutes). The first dose of test article was to be administered within 4 hours of randomization. The po treatment phase employed a double-blind, double-dummy design using matching over-encapsulated placebo and active moxifloxacin tablets. When switching from iv to po test article, the recommended interval between doses was maintained. The first po moxifloxacin dose was given in the morning 12 to 24 hours after the last iv dose.

    Number of subjects in period 1
    Omadacycline Moxifloxacin
    Started
    336
    334
    Completed
    316
    310
    Not completed
    20
    24
         Adverse event, serious fatal
    2
    2
         Consent withdrawn by subject
    3
    6
         Adverse event, non-fatal
    9
    10
         Other
    6
    5
         Lost to follow-up
    -
    1

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Omadacycline
    Reporting group description
    The ITT population included all 336 subjects randomized to the omadacycline group. The ITT population was used for analysis of demographic and baseline characteristics and efficacy. The safety population included all randomized subjects who received at least 1 dose of test article (336 subjects).

    Reporting group title
    Moxifloxacin
    Reporting group description
    The ITT population included all 334 subjects randomized to the moxifloxacin group. The ITT population was used for analysis of demographic and baseline characteristics and efficacy. The safety population included all randomized subjects who received at least 1 administration of test article (332 subjects). Two subjects were excluded from the safety population because they did not receive test article.

    Reporting group values
    Omadacycline Moxifloxacin Total
    Number of subjects
    336 334 670
    Age categorical
    Subjects were categorized as > 65 years of age in 48.2% and > 75 years of age in 18.8%. The overall mean age was 62.8 years.
    Units: Subjects
        Adults (18-64 years)
    167 167 334
        From 65-84 years
    151 158 309
        85 years and over
    18 9 27
    Age continuous
    Units: years
        arithmetic mean (standard deviation)
    63.3 ( 14.41 ) 62.2 ( 15.42 ) -
    Gender categorical
    Overall in the ITT population 51.6% of subjects were male and 48.4% were female.
    Units: Subjects
        Female
    158 166 324
        Male
    178 168 346
    Ethnicity (ITT population)
    The majority of subjects were White (99.7%) and not Hispanic or Latino (98.8%).
    Units: Subjects
        Hispanic or Latino
    4 4 8
        Not Hispanic or Latino
    332 330 662
    Race
    Units: Subjects
        White
    335 333 668
        Asian
    1 1 2
    Renal function
    Units: Subjects
        normal renal function
    170 188 358
        mild renal impairment
    123 103 226
        moderate renal impairment
    43 43 86
    Risk factors for CABP at baseline: smoking status
    Overall, 25.7% of subjects were current smokers.
    Units: Subjects
        non-smoker
    190 201 391
        current smoker
    88 84 172
        past smoker
    58 49 107
    Risk factors for CABP at baseline: pneumococcal vaccine status
    Units: Subjects
        received pneumococcal vaccine
    1 1 2
        did not receive pneumococcal vaccine
    335 333 668
    Risk factors for CABP at baseline: COVID-19 vaccine status
    Units: Subjects
        received COVID-19 vaccine
    90 72 162
        did not receive COVID-19 vaccine
    246 262 508
    Risk factors for CABP at baseline: prior lung infection
    Overall, 4.5% of subjects had a prior lung infection.
    Units: Subjects
        yes prior lung infection
    12 18 30
        no prior lung infection
    324 316 640
    Risk factors for CABP at baseline: COPD
    Overall, 7.6% of subjects had COPD.
    Units: Subjects
        yes COPD
    31 20 51
        no COPD
    305 314 619
    Risk factors for CABP at baseline: asthma
    Overall, 4.6% of subjects had asthma.
    Units: Subjects
        yes asthma
    10 21 31
        no asthma
    326 313 639
    Risk factors for CABP at baseline: chronic cough
    Units: Subjects
        yes chronic cough
    7 2 9
        no chronic cough
    329 332 661
    CABP baseline characteristics: prior antibiotic use (as randomized)
    A prior antibiotic (ie, a single dose of a short-acting antibacterial) was used in 25.0% of omadacycline subjects and 25.7% of moxifloxacin subjects.
    Units: Subjects
        prior antibiotic use
    84 84 168
        no prior antibiotic use
    252 250 502
    CABP baseline characteristics: prior antibiotic use (actual)
    Units: Subjects
        prior antibiotic use
    84 86 170
        no prior antibiotic use
    252 248 500
    CABP baseline characteristics: PORT risk class (actual)
    As required per protocol, all subjects had a PORT Risk Class of III (75.6% omadacycline, 76.6% moxifloxacin) or IV (24.4% omadacycline, 23.4% moxifloxacin), with a mean PORT score of 84.9 in the omadacycline group and 84.4 in the moxifloxacin group.
    Units: Subjects
        PORT risk class III
    254 256 510
        PORT risk class IV
    82 78 160
    CABP baseline characteristics: PORT risk class (as randomized)
    Units: Subjects
        PORT risk class III
    257 256 513
        PORT risk class IV
    79 78 157
    CABP baseline characteristics: CURB-65 score
    Less than 36% of subjects had severe CABP based on the confusion, uremia, RR, blood pressure, and age 65 or older (CURB-65) criteria (score ≥ 2).
    Units: Subjects
        CURB-65 score=0
    50 51 101
        CURB-65 score=1
    153 149 302
        CURB-65 score=2
    112 124 236
        CURB-65 score=3
    20 9 29
        CURB-65 score=4
    1 1 2
    CABP baseline characteristics: SIRS
    A majority of subjects had evidence of systemic inflammatory response syndrome (SIRS) at Baseline (78.1% of subjects).
    Units: Subjects
        yes SIRS
    257 266 523
        No SIRS
    79 68 147
    CABP baseline characteristics: bacteremia
    Units: Subjects
        yes bacteremia
    12 14 26
        no bacteremia
    324 320 644
    Radiologic assessment
    Units: Subjects
        chest x-ray
    298 309 607
        CT scan
    38 25 63
    Infiltrates at baseline
    All subjects had pulmonary infiltrates (which was a requirement to be enrolled in the study), which included 47.9% of omadacycline subjects and 44.6% of moxifloxacin subjects with multilobar infiltrates.
    Units: Subjects
        unilobar
    175 185 360
        multilobar
    161 149 310
    Presence of pleural effusion at baseline
    Pleural effusion was absent in most subjects (83.9% omadacycline, 81.7% moxifloxacin).
    Units: Subjects
        yes
    54 61 115
        no
    282 273 555
    Clinical symptoms of CABP at baseline: cough
    Units: Subjects
        mild
    12 16 28
        moderate
    211 217 428
        severe
    113 101 214
    Clinical symptoms of CABP at baseline: pleuritic chest pain
    Units: Subjects
        absent
    125 130 255
        mild
    68 83 151
        moderate
    105 91 196
        severe
    38 30 68
    Clinical symptoms of CABP at baseline: dyspnea
    Units: Subjects
        absent
    4 4 8
        mild
    42 40 82
        moderate
    206 213 419
        severe
    84 77 161
    Clinical symptoms of CABP at baseline: sputum production
    Units: Subjects
        absent
    17 28 45
        mild
    105 87 192
        moderate
    179 184 363
        severe
    35 35 70
    Subject analysis sets

    Subject analysis set title
    Intent-to-Treat (ITT) set
    Subject analysis set type
    Intention-to-treat
    Subject analysis set description
    The ITT population consisted of all randomized subjects regardless of whether or not the subject received test article.

    Subject analysis sets values
    Intent-to-Treat (ITT) set
    Number of subjects
    670
    Age categorical
    Subjects were categorized as > 65 years of age in 48.2% and > 75 years of age in 18.8%. The overall mean age was 62.8 years.
    Units: Subjects
        Adults (18-64 years)
    334
        From 65-84 years
    309
        85 years and over
    27
    Age continuous
    Units: years
        arithmetic mean (standard deviation)
    62.8 ( 14.92 )
    Gender categorical
    Overall in the ITT population 51.6% of subjects were male and 48.4% were female.
    Units: Subjects
        Female
    324
        Male
    346
    Ethnicity (ITT population)
    The majority of subjects were White (99.7%) and not Hispanic or Latino (98.8%).
    Units: Subjects
        Hispanic or Latino
    8
        Not Hispanic or Latino
    662
    Race
    Units: Subjects
        White
    668
        Asian
    2
    Renal function
    Units: Subjects
        normal renal function
    358
        mild renal impairment
    226
        moderate renal impairment
    86
    Risk factors for CABP at baseline: smoking status
    Overall, 25.7% of subjects were current smokers.
    Units: Subjects
        non-smoker
    391
        current smoker
    172
        past smoker
    107
    Risk factors for CABP at baseline: pneumococcal vaccine status
    Units: Subjects
        received pneumococcal vaccine
    2
        did not receive pneumococcal vaccine
    668
    Risk factors for CABP at baseline: COVID-19 vaccine status
    Units: Subjects
        received COVID-19 vaccine
    162
        did not receive COVID-19 vaccine
    508
    Risk factors for CABP at baseline: prior lung infection
    Overall, 4.5% of subjects had a prior lung infection.
    Units: Subjects
        yes prior lung infection
    30
        no prior lung infection
    640
    Risk factors for CABP at baseline: COPD
    Overall, 7.6% of subjects had COPD.
    Units: Subjects
        yes COPD
    51
        no COPD
    619
    Risk factors for CABP at baseline: asthma
    Overall, 4.6% of subjects had asthma.
    Units: Subjects
        yes asthma
    31
        no asthma
    639
    Risk factors for CABP at baseline: chronic cough
    Units: Subjects
        yes chronic cough
    9
        no chronic cough
    661
    CABP baseline characteristics: prior antibiotic use (as randomized)
    A prior antibiotic (ie, a single dose of a short-acting antibacterial) was used in 25.0% of omadacycline subjects and 25.7% of moxifloxacin subjects.
    Units: Subjects
        prior antibiotic use
    168
        no prior antibiotic use
    502
    CABP baseline characteristics: prior antibiotic use (actual)
    Units: Subjects
        prior antibiotic use
    170
        no prior antibiotic use
    500
    CABP baseline characteristics: PORT risk class (actual)
    As required per protocol, all subjects had a PORT Risk Class of III (75.6% omadacycline, 76.6% moxifloxacin) or IV (24.4% omadacycline, 23.4% moxifloxacin), with a mean PORT score of 84.9 in the omadacycline group and 84.4 in the moxifloxacin group.
    Units: Subjects
        PORT risk class III
    510
        PORT risk class IV
    160
    CABP baseline characteristics: PORT risk class (as randomized)
    Units: Subjects
        PORT risk class III
    513
        PORT risk class IV
    157
    CABP baseline characteristics: CURB-65 score
    Less than 36% of subjects had severe CABP based on the confusion, uremia, RR, blood pressure, and age 65 or older (CURB-65) criteria (score ≥ 2).
    Units: Subjects
        CURB-65 score=0
    101
        CURB-65 score=1
    302
        CURB-65 score=2
    236
        CURB-65 score=3
    29
        CURB-65 score=4
    2
    CABP baseline characteristics: SIRS
    A majority of subjects had evidence of systemic inflammatory response syndrome (SIRS) at Baseline (78.1% of subjects).
    Units: Subjects
        yes SIRS
    523
        No SIRS
    147
    CABP baseline characteristics: bacteremia
    Units: Subjects
        yes bacteremia
    26
        no bacteremia
    644
    Radiologic assessment
    Units: Subjects
        chest x-ray
    607
        CT scan
    63
    Infiltrates at baseline
    All subjects had pulmonary infiltrates (which was a requirement to be enrolled in the study), which included 47.9% of omadacycline subjects and 44.6% of moxifloxacin subjects with multilobar infiltrates.
    Units: Subjects
        unilobar
    360
        multilobar
    310
    Presence of pleural effusion at baseline
    Pleural effusion was absent in most subjects (83.9% omadacycline, 81.7% moxifloxacin).
    Units: Subjects
        yes
    115
        no
    555
    Clinical symptoms of CABP at baseline: cough
    Units: Subjects
        mild
    28
        moderate
    428
        severe
    214
    Clinical symptoms of CABP at baseline: pleuritic chest pain
    Units: Subjects
        absent
    255
        mild
    151
        moderate
    196
        severe
    68
    Clinical symptoms of CABP at baseline: dyspnea
    Units: Subjects
        absent
    8
        mild
    82
        moderate
    419
        severe
    161
    Clinical symptoms of CABP at baseline: sputum production
    Units: Subjects
        absent
    45
        mild
    192
        moderate
    363
        severe
    70

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Omadacycline
    Reporting group description
    The ITT population included all 336 subjects randomized to the omadacycline group. The ITT population was used for analysis of demographic and baseline characteristics and efficacy. The safety population included all randomized subjects who received at least 1 dose of test article (336 subjects).

    Reporting group title
    Moxifloxacin
    Reporting group description
    The ITT population included all 334 subjects randomized to the moxifloxacin group. The ITT population was used for analysis of demographic and baseline characteristics and efficacy. The safety population included all randomized subjects who received at least 1 administration of test article (332 subjects). Two subjects were excluded from the safety population because they did not receive test article.

    Subject analysis set title
    Intent-to-Treat (ITT) set
    Subject analysis set type
    Intention-to-treat
    Subject analysis set description
    The ITT population consisted of all randomized subjects regardless of whether or not the subject received test article.

    Primary: ECR 72-120 hr after first infusion of test article

    Close Top of page
    End point title
    ECR 72-120 hr after first infusion of test article
    End point description
    The primary efficacy outcome measure was ECR at 72 to 120 hours after administration of the first dose of test article in the ITT population. Overall, omadacycline was found to be non-inferior to moxifloxacin for the ECR assessment in the ITT population. Clinical success rates were high (89.6% omadacycline, 87.7% moxifloxacin) and comparable between both treatment groups (difference [95% CI]: 1.9 [-3.0, 6.8]). Given that the lower limit of the 95% CI for the treatment difference (omadacycline – moxifloxacin) was greater than -10%, omadacycline was considered non-inferior to moxifloxacin.
    End point type
    Primary
    End point timeframe
    72-120 hours after first infusion of test article
    End point values
    Omadacycline Moxifloxacin
    Number of subjects analysed
    336
    334
    Units: subjects
        clinical success
    301
    293
        clinical failure or indeterminate overall
    35
    41
        clinical failure
    29
    31
        indeterminate
    6
    10
    Statistical analysis title
    Primary efficacy analysis
    Statistical analysis description
    The primary efficacy analyses were based on the ITT population. The non-inferiority (NI) test was a 1-sided hypothesis test performed at the 2.5% level of significance. This NI test was based on the lower limit of the 2-sided 95% confidence interval (CI) (Miettinen & Nurminen method). The primary efficacy outcome was the percentage of subjects with a clinical success at the ECR Assessment (72-120 hours after the first infusion of test article).
    Comparison groups
    Omadacycline v Moxifloxacin
    Number of subjects included in analysis
    670
    Analysis specification
    Pre-specified
    Analysis type
    non-inferiority
    Method
    Parameter type
    Risk difference (RD)
    Point estimate
    1.9
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -3
         upper limit
    6.8

    Secondary: Overall clinical response at the PTE visit

    Close Top of page
    End point title
    Overall clinical response at the PTE visit
    End point description
    The number and percentage of subjects classified as clinical success, clinical failure, and indeterminate by the investigator’s assessment at PTE in the ITT and CE populations calculated for each treatment group was summarized. Clinical success rates were high and similar between the treatment groups at the overall PTE visit. In the ITT population, clinical success at PTE was 86.0% for omadacycline and 87.7% for moxifloxacin (difference [95% CI]: -1.7 [-6.9, 3.4]). Similar results were observed in the CE-PTE population (clinical success was observed in 94.1% of omadacycline subjects and 95.9% of moxifloxacin subjects; difference [95% CI]: -1.8 [-5.7, 2.0]).
    End point type
    Secondary
    End point timeframe
    The PTE visit occurred at 5-10 days after the last day of therapy
    End point values
    Omadacycline Moxifloxacin
    Number of subjects analysed
    336
    334
    Units: subjects
        ITT clinical success
    289
    293
        ITT clinical failure
    27
    22
        ITT indeterminate
    20
    19
    Statistical analysis title
    Clinical response at the PTE visit
    Statistical analysis description
    Difference was observed difference in overall clinical success rate at PTE between the omadacycline and moxifloxacin groups. Overall clinical response at the PTE was based on the investigator assessment at the EOT and PTE visits. Percentages were based on the number of subjects in each treatment group. 95% CI was constructed based on the Miettinen and Nurminen method without stratification.
    Comparison groups
    Omadacycline v Moxifloxacin
    Number of subjects included in analysis
    670
    Analysis specification
    Pre-specified
    Analysis type
    other [1]
    Method
    Parameter type
    Risk difference (RD)
    Point estimate
    -1.7
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -5.7
         upper limit
    3.4
    Notes
    [1] - The 95% confidence intervals are for descriptive purposes only; no conclusion of noninferiority were made.

    Secondary: All-cause mortality at 15 & 30 days after first dose of test article lost to follow-up subjects considered deceased

    Close Top of page
    End point title
    All-cause mortality at 15 & 30 days after first dose of test article lost to follow-up subjects considered deceased
    End point description
    Within 15 days after the first dose of test article, 4 subjects in each treatment group died, and 1 subject in each treatment group was lost to follow-up. Within 30 days after the first dose of test article, 5 subjects in the omadacycline group and 6 subjects in the moxifloxacin group died. In addition, 2 subjects in the omadacycline group and 3 subjects in the moxifloxacin group were lost to follow-up in this time period.
    End point type
    Secondary
    End point timeframe
    15 and 30 days after first dose of test article
    End point values
    Omadacycline Moxifloxacin
    Number of subjects analysed
    328
    322
    Units: subjects
        15 days all-cause mortality inc lost to follow-up
    5
    5
        15 days deaths inc lost to follow-up
    4
    4
        15 days lost to follow-up
    1
    1
        30 days all-cause mortality inc lost to follow-up
    7
    9
        30 days deaths inc lost to follow-up
    5
    6
        30 days lost to follow-up
    2
    3
    No statistical analyses for this end point

    Other pre-specified: Overall clinical response at PTE without resolution of all symptoms

    Close Top of page
    End point title
    Overall clinical response at PTE without resolution of all symptoms
    End point description
    Of the subjects who did not have complete resolution of symptoms at the PTE visit, a majority (83.1% omadacycline, 82.9% moxifloxacin) were determined to be clinical successes by the investigators at PTE; such subjects had residual or minimal clinical symptoms of CABP at PTE that did not require further systemic antimicrobial therapy.
    End point type
    Other pre-specified
    End point timeframe
    Post therapy evaluation (PTE; 5-10 days after the last day of therapy)
    End point values
    Omadacycline Moxifloxacin
    Number of subjects analysed
    336
    334
    Units: subjects
        clinical success
    49
    34
        clinical failure or indeterminate
    10
    7
        clinical failure
    10
    7
        indeterminate
    0
    0
    Statistical analysis title
    Clinical response at PTE w/o resolution of symptom
    Statistical analysis description
    Difference was observed difference in overall clinical success rate at PTE between the omadacycline and moxifloxacin groups. Clinical symptoms for CABP: cough, sputum production, pleuritic chest pain, and dyspnea. Resolution was defined as the absence of all baseline symptoms. Overall clinical response at the PTE was based on the investigator assessment at the EOT and PTE visits. 95% CI was constructed based on the Miettinen and Nurminen method without stratification.
    Comparison groups
    Omadacycline v Moxifloxacin
    Number of subjects included in analysis
    670
    Analysis specification
    Pre-specified
    Analysis type
    other [2]
    Method
    Parameter type
    Risk difference (RD)
    Point estimate
    0.1
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -14.6
         upper limit
    16.5
    Notes
    [2] - The 95% confidence intervals are for descriptive purposes only; no conclusions of noninferiority were made.

    Other pre-specified: Investigator assessment of clinical response at EOT visit

    Close Top of page
    End point title
    Investigator assessment of clinical response at EOT visit
    End point description
    Subjects classified as a clinical success, clinical failure, or indeterminate by the investigator’s assessment at EOT in the ITT population. The percentage of subjects in the ITT population with clinical success was similar in the omadacycline group compared to the moxifloxacin group (90.2% and 91.3%, respectively.
    End point type
    Other pre-specified
    End point timeframe
    From the first dose of test article to the EOT visit.
    End point values
    Omadacycline Moxifloxacin
    Number of subjects analysed
    336
    334
    Units: subjects
        Clinical success
    303
    305
        Clinical failure or indeterminate
    33
    29
        Clinical failure
    25
    18
        Indeterminate
    8
    11
    Statistical analysis title
    Clinical response at EOT visit
    Statistical analysis description
    Difference was observed difference in investigator assessment of clinical success rate at EOT between the omadacycline and moxifloxacin groups. Two-sided unadjusted 95% CI was constructed for the observed difference in the clinical success rate based on the Miettinen and Nurminen method without stratification.
    Comparison groups
    Omadacycline v Moxifloxacin
    Number of subjects included in analysis
    670
    Analysis specification
    Pre-specified
    Analysis type
    other
    Method
    Parameter type
    Risk difference (RD)
    Point estimate
    -1.1
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -5.6
         upper limit
    3.3

    Other pre-specified: Overall clinical response by investigator at PTE visit in subjects without resolution of all clinical symptoms (ITT population)

    Close Top of page
    End point title
    Overall clinical response by investigator at PTE visit in subjects without resolution of all clinical symptoms (ITT population)
    End point description
    Analyses of shifts from Baseline to each visit (Day 2 through the PTE visit) in the clinical symptoms of CABP were performed by treatment group for the ITT population. In general, most subjects who had cough, pleuritic chest pain, dyspnea, and phlegm/sputum considered severe at Baseline were reported to have mild to no symptoms at the EOT and PTE visits. Shifts to less severe categories were also observed in the mild and moderate categories. At the PTE visit the percentage of subjects who had resolution of all clinical symptoms in the omadacycline and moxifloxacin groups were 81.0% and 86.8%, respectively. A vast majority of subjects in either treatment group did not have a new or worsening symptom (99.7% omadacycline, 99.7% moxifloxacin). Of the subjects who did not have complete resolution of symptoms at the PTE visit, a majority (83.1% omadacycline, 82.9% moxifloxacin) were determined to be clinical successes by the investigators at PTE.
    End point type
    Other pre-specified
    End point timeframe
    From baseline (Day 2) to PTE visit
    End point values
    Omadacycline Moxifloxacin
    Number of subjects analysed
    59 [3]
    41 [4]
    Units: subjects
        clinical success
    49
    34
        clinical failure or indeterminate
    10
    7
        clinical failure
    10
    7
        indeterminate
    0
    0
    Notes
    [3] - number of subjects without resolution of symptoms at PTE
    [4] - number of subjects without resolution of symptoms at PTE
    Statistical analysis title
    Response at PTE w/o resolution of all symptoms
    Statistical analysis description
    Difference was observed difference in overall clinical success rate at PTE between the omadacycline and moxifloxacin groups. Clinical symptoms for CABP: cough, sputum production, pleuritic chest pain, and dyspnea. Resolution was defined as the absence of all baseline symptoms. Overall clinical response at the PTE was based on the investigator assessment at the EOT and PTE visits. 95% CI was constructed based on the Miettinen and Nurminen method without stratification.
    Comparison groups
    Omadacycline v Moxifloxacin
    Number of subjects included in analysis
    100
    Analysis specification
    Pre-specified
    Analysis type
    other
    Method
    Parameter type
    Risk difference (RD)
    Point estimate
    0.1
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -14.6
         upper limit
    16.5

    Other pre-specified: Concordance of ECR with overall clinical response based on investigator assessment

    Close Top of page
    End point title
    Concordance of ECR with overall clinical response based on investigator assessment
    End point description
    Among subjects with definitive assessments (ie, not indeterminate), there was generally good concordance (≥ 80%) between ECR and the later clinical assessment in each treatment group. Overall, the incidences of subjects who were programmatically determined as non-responders at ECR and later deemed clinical cures at PTE by the investigators were 5.4% for omadacycline subjects and 4.5% for moxifloxacin subjects. The incidences of subjects who were responders at ECR and later deemed clinical failures at PTE were 5.7% for omadacycline subjects and 2.4% for moxifloxacin subjects. The difference between treatment groups was driven mainly by the greater number of subjects in the omadacycline group who did not complete the PTE visit.
    End point type
    Other pre-specified
    End point timeframe
    72 to 120 hours to PTE visit
    End point values
    Omadacycline Moxifloxacin
    Number of subjects analysed
    336
    334
    Units: subjects
        ECR clinical success/PTE clinical success
    270
    275
        ECR clinical success/PTE clinical failure
    19
    8
        ECR clinical success/PTE indeterminate
    12
    10
        ECR clinical failure/PTE clinical success
    18
    15
        ECR clinical failure/PTE clinical failure
    8
    14
        ECR clinical failure/PTE indeterminate
    3
    2
        ECR indeterminate/PTE clinical success
    1
    3
        ECR indeterminate/PTE clinical failure
    0
    0
        ECR indeterminate/PTE indeterminate
    5
    7
    No statistical analyses for this end point

    Other pre-specified: Clinical response by PORT risk class

    Close Top of page
    End point title
    Clinical response by PORT risk class
    End point description
    ECR (at 72 to 120 hours after the first infusion of test article) and overall assessment of clinical response (based on the investigator’s assessment) at the PTE visit across PORT Risk Class in the ITT population. In general, comparable results were observed between PORT Risk Class III and Class IV scores for both the ECR and PTE assessments.
    End point type
    Other pre-specified
    End point timeframe
    ECR (72-120 hours after first infusion of test article) to PTE visit
    End point values
    Omadacycline Moxifloxacin
    Number of subjects analysed
    336
    334
    Units: subjects
        ECR PORT risk class III clinical success
    230
    229
        ECR PORT risk class IV clinical success
    71
    64
        PTE PORT risk class III clinical success
    197
    206
        PTE PORT risk class IV clinical success
    60
    54
    Statistical analysis title
    Clinical response by PORT risk class
    Statistical analysis description
    Difference was observed difference in early clinical success rate or overall clinical response rate at PTE between the omadacycline and moxifloxacin groups. 95% CI within each type of PORT Risk Class was constructed based on the Miettinen and Nurminen method without stratification.
    Comparison groups
    Omadacycline v Moxifloxacin
    Number of subjects included in analysis
    670
    Analysis specification
    Pre-specified
    Analysis type
    other
    Method
    Parameter type
    Risk difference (RD)
    Point estimate
    1.1
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -4.2
         upper limit
    6.4

    Other pre-specified: Clinical response by prior antibiotic use

    Close Top of page
    End point title
    Clinical response by prior antibiotic use
    End point description
    ECR (at 72 to 120 hours after the first infusion of test article) and overall assessment of clinical response (based on the investigator’s assessment) at the PTE visit across prior antibiotic use in the ITT population. Comparable results were observed between those who did and did not receive a prior antibiotic (ie, a single dose short-acting antibiotic within 72 hours prior to the first dose of test article) for both the ECR and PTE assessments.
    End point type
    Other pre-specified
    End point timeframe
    ECR (72-120 hours after first infusion of test article) to PTE visit
    End point values
    Omadacycline Moxifloxacin
    Number of subjects analysed
    336
    334
    Units: subjects
        ECR received prior antibiotics/clinical success
    72
    73
        ECR no prior antibiotics/clinical success
    229
    220
        PTE received prior antibiotics/clinical success
    69
    75
        PTE no prior antibiotics/clinical success
    220
    218
    Statistical analysis title
    ECR at PTE visit based on prior antibiotic use
    Statistical analysis description
    Difference was observed difference in early clinical success rate or overall clinical response rate at the PTE between the omadacycline and moxifloxacin groups. 95% CI within each type of prior antibiotics use (yes/no) was constructed based on the Miettinen and Nurminen method without stratification.
    Comparison groups
    Omadacycline v Moxifloxacin
    Number of subjects included in analysis
    670
    Analysis specification
    Pre-specified
    Analysis type
    other
    Method
    Parameter type
    Risk difference (RD)
    Point estimate
    0.8
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -10.2
         upper limit
    11.8

    Other pre-specified: Clinical success in subjects with SIRS and by CURB-65 score

    Close Top of page
    End point title
    Clinical success in subjects with SIRS and by CURB-65 score
    End point description
    In subjects with SIRS, the ECR assessment of clinical success was reported in 90.3% omadacycline subjects and 88.0% moxifloxacin subjects. At PTE, the corresponding clinical success rates were 85.2% and 87.6%. In addition, generally comparable results were observed between different CURB-65 scores, although there were relatively few subjects with CURB-65 scores of 3 or 4.
    End point type
    Other pre-specified
    End point timeframe
    From ECR (72-120 after first infusion of test article) to PTE visit
    End point values
    Omadacycline Moxifloxacin
    Number of subjects analysed
    336
    334
    Units: subjects
        SIRS at baseline ECR clinical success
    232
    234
        SIRS at baseline PTE clinical success
    219
    233
        ECR CURB-65 score=0 clinical success
    46
    44
        ECR CURB-65 score=1 clinical success
    135
    138
        ECR CURB-65 score=2 clinical success
    99
    103
        ECR CURB-65 score=3 clinical success
    20
    7
        ECR CURB-65 score=4 clinical success
    1
    1
        PTE CURB-65 score=0 clinical success
    41
    46
        PTE CURB-65 score=1 clinical success
    138
    137
        PTE CURB-65 score=2 clinical success
    91
    102
        PTE CURB-65 score=3 clinical success
    18
    7
        PTE CURB-65 score=4 clinical success
    1
    1
    Statistical analysis title
    ECR at PTE visit in subjects with SIRS & CURB-65
    Statistical analysis description
    Difference was observed difference in early clinical success rate or overall clinical response rate at the PTE between the omadacycline and moxifloxacin groups. 95% CI within each subgroup was constructed based on the Miettinen and Nurminen method without stratification.
    Comparison groups
    Omadacycline v Moxifloxacin
    Number of subjects included in analysis
    670
    Analysis specification
    Pre-specified
    Analysis type
    other
    Method
    Parameter type
    Risk difference (RD)
    Point estimate
    2.3
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -3.1
         upper limit
    7.8

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    A treatment-emergent AE was defined as any AE that newly appeared, increased in frequency, or worsened in severity on or after the initiation of active test article.
    Adverse event reporting additional description
    The Safety population consisted of all randomized subjects who received test article. An AE was considered treatment-emergent if the AE start date and time was on or after the start date and time of the first infusion of active test article.
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    27.0
    Reporting groups
    Reporting group title
    Omadacycline
    Reporting group description
    Safety population

    Reporting group title
    Moxifloxacin
    Reporting group description
    Safety population

    Serious adverse events
    Omadacycline Moxifloxacin
    Total subjects affected by serious adverse events
         subjects affected / exposed
    17 / 336 (5.06%)
    15 / 332 (4.52%)
         number of deaths (all causes)
    6
    6
         number of deaths resulting from adverse events
    6
    6
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Metastases to liver
         subjects affected / exposed
    1 / 336 (0.30%)
    0 / 332 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    Cardiac disorders
    Atrial fibrillation
         subjects affected / exposed
    1 / 336 (0.30%)
    0 / 332 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cardiac failure
         subjects affected / exposed
    1 / 336 (0.30%)
    2 / 332 (0.60%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Cardiogenic shock
         subjects affected / exposed
    1 / 336 (0.30%)
    0 / 332 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    Pericardial effusion
         subjects affected / exposed
    1 / 336 (0.30%)
    0 / 332 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cardiac arrest
         subjects affected / exposed
    0 / 336 (0.00%)
    2 / 332 (0.60%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 2
    Cardiopulmonary failure
         subjects affected / exposed
    0 / 336 (0.00%)
    1 / 332 (0.30%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Nervous system disorders
    Cerebral infarction
         subjects affected / exposed
    1 / 336 (0.30%)
    0 / 332 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    Epilepsy
         subjects affected / exposed
    0 / 336 (0.00%)
    1 / 332 (0.30%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    General disorders and administration site conditions
    Death
         subjects affected / exposed
    1 / 336 (0.30%)
    0 / 332 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    Multiple organ dysfunction syndrome
         subjects affected / exposed
    0 / 336 (0.00%)
    1 / 332 (0.30%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Gastrointestinal disorders
    Gastrointestinal haemorrhage
         subjects affected / exposed
    1 / 336 (0.30%)
    0 / 332 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    Chronic respiratory failure
         subjects affected / exposed
    1 / 336 (0.30%)
    0 / 332 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Organising pneumonia
         subjects affected / exposed
    1 / 336 (0.30%)
    0 / 332 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pulmonary embolism
         subjects affected / exposed
    1 / 336 (0.30%)
    0 / 332 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    Acute respiratory failure
         subjects affected / exposed
    0 / 336 (0.00%)
    2 / 332 (0.60%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Bronchiectasis
         subjects affected / exposed
    0 / 336 (0.00%)
    1 / 332 (0.30%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Haemoptysis
         subjects affected / exposed
    0 / 336 (0.00%)
    1 / 332 (0.30%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Psychiatric disorders
    Psychotic disorder
         subjects affected / exposed
    0 / 336 (0.00%)
    1 / 332 (0.30%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Renal and urinary disorders
    Ureterolithiasis
         subjects affected / exposed
    1 / 336 (0.30%)
    0 / 332 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Musculoskeletal and connective tissue disorders
    Arthritis
         subjects affected / exposed
    0 / 336 (0.00%)
    1 / 332 (0.30%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Infections and infestations
    Pneumonia
         subjects affected / exposed
    2 / 336 (0.60%)
    2 / 332 (0.60%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 2
         deaths causally related to treatment / all
    0 / 1
    0 / 1
    COVID-19
         subjects affected / exposed
    1 / 336 (0.30%)
    2 / 332 (0.60%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Infectious pleural effusion
         subjects affected / exposed
    1 / 336 (0.30%)
    0 / 332 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Septic shock
         subjects affected / exposed
    1 / 336 (0.30%)
    1 / 332 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Urinary tract infection
         subjects affected / exposed
    1 / 336 (0.30%)
    0 / 332 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Empyema
         subjects affected / exposed
    0 / 336 (0.00%)
    1 / 332 (0.30%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Lung abscess
         subjects affected / exposed
    0 / 336 (0.00%)
    1 / 332 (0.30%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pyoderma streptococcal
         subjects affected / exposed
    0 / 336 (0.00%)
    1 / 332 (0.30%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 0.3%
    Non-serious adverse events
    Omadacycline Moxifloxacin
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    93 / 336 (27.68%)
    78 / 332 (23.49%)
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Lung neoplasm malignant
         subjects affected / exposed
    1 / 336 (0.30%)
    0 / 332 (0.00%)
         occurrences all number
    1
    0
    Polycythaemia vera
         subjects affected / exposed
    1 / 336 (0.30%)
    0 / 332 (0.00%)
         occurrences all number
    1
    0
    Vascular disorders
    Hypertension
         subjects affected / exposed
    3 / 336 (0.89%)
    1 / 332 (0.30%)
         occurrences all number
    3
    1
    Hypertensive crisis
         subjects affected / exposed
    2 / 336 (0.60%)
    1 / 332 (0.30%)
         occurrences all number
    2
    1
    Deep vein thrombosis
         subjects affected / exposed
    1 / 336 (0.30%)
    0 / 332 (0.00%)
         occurrences all number
    1
    0
    Aortic dilatation
         subjects affected / exposed
    0 / 336 (0.00%)
    1 / 332 (0.30%)
         occurrences all number
    0
    1
    Hypotension
         subjects affected / exposed
    0 / 336 (0.00%)
    1 / 332 (0.30%)
         occurrences all number
    0
    1
    Thrombophlebitis
         subjects affected / exposed
    0 / 336 (0.00%)
    1 / 332 (0.30%)
         occurrences all number
    0
    1
    General disorders and administration site conditions
    Chest pain
         subjects affected / exposed
    3 / 336 (0.89%)
    0 / 332 (0.00%)
         occurrences all number
    3
    0
    Catheter site related reaction
         subjects affected / exposed
    2 / 336 (0.60%)
    0 / 332 (0.00%)
         occurrences all number
    2
    0
    Administration site reaction
         subjects affected / exposed
    1 / 336 (0.30%)
    3 / 332 (0.90%)
         occurrences all number
    1
    3
    Oedema peripheral
         subjects affected / exposed
    1 / 336 (0.30%)
    1 / 332 (0.30%)
         occurrences all number
    1
    1
    Pyrexia
         subjects affected / exposed
    1 / 336 (0.30%)
    0 / 332 (0.00%)
         occurrences all number
    1
    0
    Catheter site erythema
         subjects affected / exposed
    0 / 336 (0.00%)
    1 / 332 (0.30%)
         occurrences all number
    0
    1
    Chest discomfort
         subjects affected / exposed
    0 / 336 (0.00%)
    2 / 332 (0.60%)
         occurrences all number
    0
    2
    Infusion site erythema
         subjects affected / exposed
    0 / 336 (0.00%)
    1 / 332 (0.30%)
         occurrences all number
    0
    1
    Infusion site reaction
         subjects affected / exposed
    0 / 336 (0.00%)
    2 / 332 (0.60%)
         occurrences all number
    0
    2
    Malaise
         subjects affected / exposed
    0 / 336 (0.00%)
    1 / 332 (0.30%)
         occurrences all number
    0
    1
    Peripheral swelling
         subjects affected / exposed
    0 / 336 (0.00%)
    1 / 332 (0.30%)
         occurrences all number
    0
    1
    Reproductive system and breast disorders
    Benign prostatic hyperplasia
         subjects affected / exposed
    0 / 336 (0.00%)
    1 / 332 (0.30%)
         occurrences all number
    0
    1
    Respiratory, thoracic and mediastinal disorders
    Chronic obstructive pulmonary disease
         subjects affected / exposed
    5 / 336 (1.49%)
    1 / 332 (0.30%)
         occurrences all number
    5
    1
    Bronchial obstruction
         subjects affected / exposed
    1 / 336 (0.30%)
    0 / 332 (0.00%)
         occurrences all number
    1
    0
    Cough
         subjects affected / exposed
    1 / 336 (0.30%)
    0 / 332 (0.00%)
         occurrences all number
    1
    0
    Dyspnoea
         subjects affected / exposed
    1 / 336 (0.30%)
    2 / 332 (0.60%)
         occurrences all number
    1
    2
    Pleural effusion
         subjects affected / exposed
    1 / 336 (0.30%)
    1 / 332 (0.30%)
         occurrences all number
    1
    1
    Pulmonary infarction
         subjects affected / exposed
    1 / 336 (0.30%)
    0 / 332 (0.00%)
         occurrences all number
    1
    0
    Haemoptysis
         subjects affected / exposed
    0 / 336 (0.00%)
    1 / 332 (0.30%)
         occurrences all number
    0
    1
    Oropharyngeal pain
         subjects affected / exposed
    0 / 336 (0.00%)
    1 / 332 (0.30%)
         occurrences all number
    0
    1
    Rhinorrhoea
         subjects affected / exposed
    0 / 336 (0.00%)
    1 / 332 (0.30%)
         occurrences all number
    0
    1
    Psychiatric disorders
    Insomnia
         subjects affected / exposed
    2 / 336 (0.60%)
    7 / 332 (2.11%)
         occurrences all number
    2
    7
    Delirium tremens
         subjects affected / exposed
    1 / 336 (0.30%)
    0 / 332 (0.00%)
         occurrences all number
    1
    0
    Initial insomnia
         subjects affected / exposed
    1 / 336 (0.30%)
    0 / 332 (0.00%)
         occurrences all number
    1
    0
    Restlessness
         subjects affected / exposed
    1 / 336 (0.30%)
    0 / 332 (0.00%)
         occurrences all number
    1
    0
    Sleep disorder
         subjects affected / exposed
    1 / 336 (0.30%)
    0 / 332 (0.00%)
         occurrences all number
    1
    0
    Psychotic disorder
         subjects affected / exposed
    0 / 336 (0.00%)
    1 / 332 (0.30%)
         occurrences all number
    0
    2
    Investigations
    Aspartate aminotransferase increased
         subjects affected / exposed
    7 / 336 (2.08%)
    0 / 332 (0.00%)
         occurrences all number
    7
    0
    Alanine aminotransferase increased
         subjects affected / exposed
    6 / 336 (1.79%)
    1 / 332 (0.30%)
         occurrences all number
    6
    1
    Blood creatinine increased
         subjects affected / exposed
    2 / 336 (0.60%)
    0 / 332 (0.00%)
         occurrences all number
    2
    0
    Gamma-glutamyltransferase increased
         subjects affected / exposed
    2 / 336 (0.60%)
    1 / 332 (0.30%)
         occurrences all number
    2
    1
    Platelet count increased
         subjects affected / exposed
    2 / 336 (0.60%)
    2 / 332 (0.60%)
         occurrences all number
    2
    2
    White blood cell count increased
         subjects affected / exposed
    2 / 336 (0.60%)
    0 / 332 (0.00%)
         occurrences all number
    2
    0
    Blood pressure increased
         subjects affected / exposed
    1 / 336 (0.30%)
    0 / 332 (0.00%)
         occurrences all number
    1
    0
    Blood urea increased
         subjects affected / exposed
    1 / 336 (0.30%)
    0 / 332 (0.00%)
         occurrences all number
    1
    0
    Creatinine renal clearance decreased
         subjects affected / exposed
    1 / 336 (0.30%)
    0 / 332 (0.00%)
         occurrences all number
    1
    0
    Electrocardiogram T wave abnormal
         subjects affected / exposed
    1 / 336 (0.30%)
    0 / 332 (0.00%)
         occurrences all number
    1
    0
    International normalised ratio increased
         subjects affected / exposed
    1 / 336 (0.30%)
    0 / 332 (0.00%)
         occurrences all number
    1
    0
    Blood creatine phosphokinase increased
         subjects affected / exposed
    0 / 336 (0.00%)
    1 / 332 (0.30%)
         occurrences all number
    0
    1
    Blood potassium increased
         subjects affected / exposed
    0 / 336 (0.00%)
    1 / 332 (0.30%)
         occurrences all number
    0
    1
    Human chorionic gonadotropin increased
         subjects affected / exposed
    0 / 336 (0.00%)
    1 / 332 (0.30%)
         occurrences all number
    0
    1
    Influenza A virus test positive
         subjects affected / exposed
    0 / 336 (0.00%)
    1 / 332 (0.30%)
         occurrences all number
    0
    1
    Injury, poisoning and procedural complications
    Limb injury
         subjects affected / exposed
    0 / 336 (0.00%)
    1 / 332 (0.30%)
         occurrences all number
    0
    1
    Cardiac disorders
    Atrial fibrillation
         subjects affected / exposed
    2 / 336 (0.60%)
    2 / 332 (0.60%)
         occurrences all number
    3
    2
    Cardiac failure
         subjects affected / exposed
    1 / 336 (0.30%)
    1 / 332 (0.30%)
         occurrences all number
    2
    3
    Angina pectoris
         subjects affected / exposed
    1 / 336 (0.30%)
    0 / 332 (0.00%)
         occurrences all number
    1
    0
    Cardiac failure congestive
         subjects affected / exposed
    1 / 336 (0.30%)
    0 / 332 (0.00%)
         occurrences all number
    1
    0
    Cardiomyopathy
         subjects affected / exposed
    1 / 336 (0.30%)
    0 / 332 (0.00%)
         occurrences all number
    1
    0
    Tachycardia
         subjects affected / exposed
    0 / 336 (0.00%)
    1 / 332 (0.30%)
         occurrences all number
    0
    1
    Nervous system disorders
    Headache
         subjects affected / exposed
    12 / 336 (3.57%)
    15 / 332 (4.52%)
         occurrences all number
    12
    15
    Dizziness
         subjects affected / exposed
    1 / 336 (0.30%)
    2 / 332 (0.60%)
         occurrences all number
    1
    2
    Brain oedema
         subjects affected / exposed
    0 / 336 (0.00%)
    1 / 332 (0.30%)
         occurrences all number
    0
    1
    Hypoxic-ischaemic encephalopathy
         subjects affected / exposed
    0 / 336 (0.00%)
    1 / 332 (0.30%)
         occurrences all number
    0
    1
    Paraesthesia
         subjects affected / exposed
    0 / 336 (0.00%)
    1 / 332 (0.30%)
         occurrences all number
    0
    1
    Tremor
         subjects affected / exposed
    0 / 336 (0.00%)
    1 / 332 (0.30%)
         occurrences all number
    0
    1
    Blood and lymphatic system disorders
    Anaemia
         subjects affected / exposed
    3 / 336 (0.89%)
    1 / 332 (0.30%)
         occurrences all number
    3
    1
    Thrombocytosis
         subjects affected / exposed
    1 / 336 (0.30%)
    0 / 332 (0.00%)
         occurrences all number
    1
    0
    Hypochromasia
         subjects affected / exposed
    0 / 336 (0.00%)
    1 / 332 (0.30%)
         occurrences all number
    0
    1
    Leukocytosis
         subjects affected / exposed
    0 / 336 (0.00%)
    1 / 332 (0.30%)
         occurrences all number
    0
    1
    Ear and labyrinth disorders
    Hypoacusis
         subjects affected / exposed
    1 / 336 (0.30%)
    0 / 332 (0.00%)
         occurrences all number
    1
    0
    Tinnitus
         subjects affected / exposed
    1 / 336 (0.30%)
    0 / 332 (0.00%)
         occurrences all number
    1
    0
    Eye disorders
    Cataract
         subjects affected / exposed
    1 / 336 (0.30%)
    0 / 332 (0.00%)
         occurrences all number
    1
    0
    Eye oedema
         subjects affected / exposed
    0 / 336 (0.00%)
    1 / 332 (0.30%)
         occurrences all number
    0
    1
    Gastrointestinal disorders
    Constipation
         subjects affected / exposed
    3 / 336 (0.89%)
    0 / 332 (0.00%)
         occurrences all number
    3
    0
    Nausea
         subjects affected / exposed
    2 / 336 (0.60%)
    5 / 332 (1.51%)
         occurrences all number
    2
    5
    Abdominal pain
         subjects affected / exposed
    1 / 336 (0.30%)
    1 / 332 (0.30%)
         occurrences all number
    1
    1
    Dyspepsia
         subjects affected / exposed
    1 / 336 (0.30%)
    2 / 332 (0.60%)
         occurrences all number
    1
    2
    Abdominal discomfort
         subjects affected / exposed
    0 / 336 (0.00%)
    4 / 332 (1.20%)
         occurrences all number
    0
    4
    Abdominal pain upper
         subjects affected / exposed
    0 / 336 (0.00%)
    2 / 332 (0.60%)
         occurrences all number
    0
    2
    Diarrhoea
         subjects affected / exposed
    0 / 336 (0.00%)
    10 / 332 (3.01%)
         occurrences all number
    0
    10
    Dry mouth
         subjects affected / exposed
    0 / 336 (0.00%)
    1 / 332 (0.30%)
         occurrences all number
    0
    1
    Vomiting
         subjects affected / exposed
    0 / 336 (0.00%)
    1 / 332 (0.30%)
         occurrences all number
    0
    1
    Hepatobiliary disorders
    Hepatic cyst
         subjects affected / exposed
    1 / 336 (0.30%)
    0 / 332 (0.00%)
         occurrences all number
    1
    0
    Hepatic steatosis
         subjects affected / exposed
    0 / 336 (0.00%)
    1 / 332 (0.30%)
         occurrences all number
    0
    1
    Skin and subcutaneous tissue disorders
    Hyperhidrosis
         subjects affected / exposed
    1 / 336 (0.30%)
    0 / 332 (0.00%)
         occurrences all number
    1
    0
    Dermatitis allergic
         subjects affected / exposed
    0 / 336 (0.00%)
    1 / 332 (0.30%)
         occurrences all number
    0
    1
    Erythema
         subjects affected / exposed
    0 / 336 (0.00%)
    3 / 332 (0.90%)
         occurrences all number
    0
    3
    Pruritus
         subjects affected / exposed
    0 / 336 (0.00%)
    1 / 332 (0.30%)
         occurrences all number
    0
    1
    Rash
         subjects affected / exposed
    0 / 336 (0.00%)
    1 / 332 (0.30%)
         occurrences all number
    0
    1
    Renal and urinary disorders
    Acute kidney injury
         subjects affected / exposed
    2 / 336 (0.60%)
    0 / 332 (0.00%)
         occurrences all number
    2
    0
    Nephropathy
         subjects affected / exposed
    0 / 336 (0.00%)
    1 / 332 (0.30%)
         occurrences all number
    0
    1
    Renal cyst
         subjects affected / exposed
    0 / 336 (0.00%)
    1 / 332 (0.30%)
         occurrences all number
    0
    1
    Musculoskeletal and connective tissue disorders
    Back pain
         subjects affected / exposed
    1 / 336 (0.30%)
    1 / 332 (0.30%)
         occurrences all number
    1
    1
    Infections and infestations
    COVID-19
         subjects affected / exposed
    10 / 336 (2.98%)
    2 / 332 (0.60%)
         occurrences all number
    11
    4
    Urinary tract infection
         subjects affected / exposed
    2 / 336 (0.60%)
    1 / 332 (0.30%)
         occurrences all number
    3
    1
    Acute sinusitis
         subjects affected / exposed
    1 / 336 (0.30%)
    0 / 332 (0.00%)
         occurrences all number
    1
    0
    Fungaemia
         subjects affected / exposed
    1 / 336 (0.30%)
    0 / 332 (0.00%)
         occurrences all number
    1
    0
    Ophthalmic herpes simplex
         subjects affected / exposed
    1 / 336 (0.30%)
    0 / 332 (0.00%)
         occurrences all number
    1
    0
    Cystitis
         subjects affected / exposed
    0 / 336 (0.00%)
    1 / 332 (0.30%)
         occurrences all number
    0
    1
    Pyelonephritis
         subjects affected / exposed
    0 / 336 (0.00%)
    1 / 332 (0.30%)
         occurrences all number
    0
    1
    Urinary tract candidiasis
         subjects affected / exposed
    0 / 336 (0.00%)
    1 / 332 (0.30%)
         occurrences all number
    0
    1
    Metabolism and nutrition disorders
    Diabetes mellitus
         subjects affected / exposed
    1 / 336 (0.30%)
    0 / 332 (0.00%)
         occurrences all number
    1
    0
    Gout
         subjects affected / exposed
    1 / 336 (0.30%)
    0 / 332 (0.00%)
         occurrences all number
    1
    0
    Hypokalaemia
         subjects affected / exposed
    1 / 336 (0.30%)
    2 / 332 (0.60%)
         occurrences all number
    1
    2
    Hypomagnesaemia
         subjects affected / exposed
    1 / 336 (0.30%)
    0 / 332 (0.00%)
         occurrences all number
    1
    0
    Hypoproteinaemia
         subjects affected / exposed
    0 / 336 (0.00%)
    1 / 332 (0.30%)
         occurrences all number
    0
    1

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    19 Nov 2020
    Exclusion criterion 17 was expanded to include those who are allergic to any of the components of the test articles. Infusion time of omadacycline was clarified to match the US FDA-approved label. A section was added to detail the clinical events committee (CEC) that was to adjudicate all cases of mortality in the study to determine cause and relatedness to study drug. Schedule of events was updated to remove the Investigator's Assessment of Clinical Response at the Final Follow-up visit to be consistent with the body of the protocol.

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 04 12:35:26 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA